Results 121 to 130 of about 8,927 (183)

Impact of Biologic Treatment Duration on Drug-Free Remission in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study. [PDF]

Dermatol Ther (Heidelb)
Hsu CC, Huang YH, Tsai TF.
europepmc   +1 more source

Clinical and MRI remission in axial spondyloarthritis: one-year outcomes and predictors from the TRACE treat-to-target study with secukinumab. [PDF]

Arthritis Res Ther
Vladimirova N, Østergaard M, Georgiadis S, Seven S, Møller JM, Jensen B, Østgård R, Poggenborg R, Madsen OR, Hendricks O, Brix L, Pedersen SJ.   +11 more
europepmc   +1 more source

Case Report: Secukinumab Experience in a Patient With Coexistence of Systemic Lupus Erythematosus, Ankylosing Spondylitis, and Antiphospholipid Antibody Syndrome. [PDF]

Case Rep Rheumatol
Basaran E, Bayrak BY, Karadag DT, Yazici A, Cefle A.   +4 more
europepmc   +1 more source

Crohn's Disease and Axial Spondyloarthritis: From Systemic Inflammation to Amyloidosis. [PDF]

J Clin Med
Kutsakina DA, Chernichkina AD, Nikolaeva NA, Voronkova OO, Tashchyan OV, Mnatsakanyan MG, Belenkov YN, Osminin SV, Vetshev FP, Bilyalov IR, Panferov AS.   +10 more
europepmc   +1 more source

Case Report: Secukinumab induced pustular eruption in a patient with ankylosing spondylitis. [PDF]

Front Med (Lausanne)
Tang Z, Liu X.
europepmc   +1 more source

Longitudinal plasma proteomics identifies diagnostic and response-associated inflammatory and immune biomarkers in psoriasis following secukinumab therapy. [PDF]

Front Immunol
Zhang H, Yang R, Ma Y, Yang J, Yang B, Dong L, Yu N.   +6 more
europepmc   +1 more source

Efficacy of tofacitinib in the treatment of refractory palmoplantar psoriasis (non-pustular): case report and literature review. [PDF]

An Bras Dermatol
Sakiyama PH, Miot LDB, Miot HA.
europepmc   +1 more source

Effect of secukinumab dose escalation on MRI-detected inflammation and structural damage in axial spondyloarthritis: a clinical, investigator-initiated, treat-to-target study (TRACE). [PDF]

RMD Open
Vladimirova N, Østergaard M, Seven S, Møller JM, Jensen B, Østgård R, Poggenborg R, Madsen OR, Hendricks O, Brix L, Georgiadis S, Pedersen SJ.   +11 more
europepmc   +1 more source

The role of interleukin-17 inhibition in systemic lupus erythematosus-paradoxical hindrance or new therapeutic potential? Results from a systematic literature review and mendelian randomization. [PDF]

Front Immunol
Nagra D, Zuckerman B, Odia J, Patel S, Ong M, Adas M, Yang Z, Bechman K, Russell M, Bhandari S, Rosa C, Banerjee S, Blake T, Gullick N, Kasavkar G, Wincup C.   +15 more
europepmc   +1 more source

The IL-23/IL-17 axis in Behçet's syndrome pathogenesis: from immunological perspectives to therapeutic implications. [PDF]

Front Immunol
Naffaa ME, Hassan F, Omar M, Abacar K, McGonagle D.   +4 more
europepmc   +1 more source